Name
RF2-02: Pooled analysis of the BrighTNess, CALGB 40603 (Alliance), and GeparSixto clinical trials identifies the impact of neoadjuvant carboplatin on pCR and survival in early-stage triple-negative breast cancer Commentary by: Joseph Sparano, MD, FACP
Date & Time
Monday, December 1, 2025
Speakers
Virtual Session Link
Total Minutes
04:59
OnDemand Video URL